Topical Vancomycin Reduces Surgical Wound Infections Without Increasing Kidney Injury, suggests study
A new study published in The Annals of Thoracic Surgery showed that topical vancomycin markedly decreased the incidence of surgical wound infections (SWI) of grade 2 or above, without elevating the likelihood of acute kidney injury (AKI).
Infections of the sternal wound represent serious complications after cardiac surgery, leading to greater morbidity, extended hospital stays, and increased healthcare expenses. Although surgical methods and perioperative antibiotic prophylaxis have improved, preventing postoperative infections continues to be difficult. The use of topical vancomycin has been proposed as a preventive measure due to its broad-spectrum effectiveness against Gram-positive bacteria, especially staphylococci. Its potential to reduce sternal wound infections of grade 2 or higher requires clinical investigation. Thereby, this study assessed the efficacy and safety of applying vancomycin paste topically on the sternal edges to prevent sternal wound infection.
This trial randomly assigned 360 adult patients undergoing elective full sternotomy cardiac surgery in a 1:1 ratio to receive either vancomycin paste or normal saline. The primary outcome measured was the incidence of surgical wound infection within 90 days following surgery. Secondary outcomes comprised postoperative acute kidney injury, development of resistant pathogens, and systemic exposure to vancomycin.
The occurrence of grade 2 or higher sternal wound infection within 90 days was notably lower in the vancomycin group compared to the placebo group (1 out of 180, 0.6% versus 7 out of 180, 3.9%, p = .031). The sub-distribution hazard ratio was 0.14 (p = .065). The rate of deep SWI was 0.6% when compared to 2.8% (p = .099).
The frequency of acute kidney injury was similar between the two groups (31.7% versus 28.9%, p = .251), including among patients with chronic kidney disease (CKD) stages 3 or higher. Systemic vancomycin levels were minimal and decreased over time in patients not receiving dialysis. However, concentrations exceeding 10-20 mg/L remained in some individuals undergoing hemodialysis.
3 instances of vancomycin-resistant Enterococcus from different sources were detected in the vancomycin-treated patients with CKD stage 3 or above or those on hemodialysis. Overall, the application of topical vancomycin decreased the occurrence of grade 2 or more severe surgical wound infections without elevating the likelihood of acute kidney injury. Systemic absorption was minimal, apart from in patients receiving hemodialysis.
Source:
Tsai, M.-T., Li, C.-Y., Chen, Y.-W., Hu, Y.-N., Kan, C.-D., Chou, C.-H., & Roan, J.-N. (2026). Topical vancomycin for prevention of grade 2 or higher sternal wound infection after cardiac surgery: A randomized controlled trial. The Annals of Thoracic Surgery. https://doi.org/10.1016/j.athoracsur.2026.09.057
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.